6:19 PM
 | 
May 24, 2012
 |  BC Extra  |  Company News

FDA panel backs accelerated approval for tafamidis

FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 13-4 that surrogate endpoint data for tafamidis from Pfizer Inc. (NYSE:PFE) were robust enough to predict a clinical benefit in patients with transthyretin (TTR) familial amyloid polyneuropathy (FAP). The vote could pave the path for accelerated approval of...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >